Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPSMA 7.3 PET/MRI in Biochemically Recurrent Prostate Cancer
NCT04978675Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Positive Predictive Value up to 6 months. Started Aug 2021; status: completed.
Beyond the preview
Go deeper on NCT04978675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978675.